oren becker vidacDr. Becker joined Vidac Pharmaceuticals as President and Chief Executive Officer in 2013. Dr. Becker brings more than 20 years of biopharmaceutical industry entrepreneurship and leadership experience to Vidac, with expertise in the discovery and development of innovative novel pharmaceuticals. Dr. Becker led or co-led more than $2B worth of deals with GSK, Amgen, Teva, Clevexel, and CFFT. Dr. Becker was a founder, Director and Chief Science Officer of Predix Pharmaceuticals (Lexington, MA and Ramat-Gan, Israel), a GPCR-focused neurology play, which was acquired by Epix Pharmaceuticals (NASDAQ:EPIX). Subsequently he served as the CSO of Epix. Under his leadership 5 novel drugs were discovered and introduced into clinical development (Phases 1 to 3).  Dr. Becker was also the founder, Director and Chief Executive Officer of Dynamix Pharmaceuticals, a cancer and autoimmune drug discovery and development company, and is a co-founder and a member of the Board of Directors of Immunity Pharma, which is developing a novel drug for ALS. Dr. Becker was a professor at Tel-Aviv University and at Harvard University. He holds a PhD from the Hebrew University of Jerusalem, and a post-doctoral training from Harvard University. Dr. Becker has published more than 50 scientific papers, has co-edited two books, and is an inventor on numerous patents.